Clinical Trials

Medicenna recognizes that patient participation in clinical trials is critical in order to advance treatment for cancer and is developing its lead product MDNA55 in the clinic for cancers that have a significant unmet medical need. MDNA55 is currently being studied in clinical trials for treatment of CNS cancers.

Phase 2 Clinical Trial Open to Enrollment

In April 2017 Medicenna announced that it had treated the first patient in its Phase 2 trial of MDNA55 in adults with recurrent Glioblastoma where MDNA55 is administered intratumorally using one infusion.

Find Open Clinical Trials

For more information about this study or to find out if you could qualify please contact a participating hospital or visit trial record (NCT02858895) on clinicaltrials.gov. You can also search clinicaltrials.gov to find out if other clinical trials exist for a specific medicine for a particular disease.

Hospitals Participating In This Clinical Trial Include:

University of California San Francisco
San Francisco, California,
United States, 94143

Contact: Thelma Munoz, Thelma.Munoz@ucsf.edu
Phone: 415-353-2523
Principal Investigator: Nicholas Butowski, MD

John Wayne Cancer Institute at Providence Saint John’s Health Center
Santa Monica, California,
United States, 90404

Contact: Mini Jaya Gill, jaya.gill@providence.org
Phone: 310-582-7437
Principal Investigator: Achal Achrol, MD

Marcus Neuroscience Institute at Boca Raton Regional Hospital
Boca Raton, Florida,
United States, 33486

Contact: Pilar Zuniga, MD, PZuniga@brrh.com
Phone: 561-955-4800
Principal Investigator: Frank Vrionis, MD

New York
Weill Cornell – New York Presbyterian Hospital
New York, New York,
United States, 10022

Contact: Mary O’Hehir, MAO2037@med.cornell.edu
Phone: 212-746-7373

Contact: Alyson Hignight, ALH3031@med.cornell.edu
Phone: 212-746-1788
Principal Investigator: Mark Souweidane, MD

North Carolina
Duke University Medical Center
Durham, North Carolina,
United States, 27710

Contact: Brain Tumor Center
Phone: 919-684-5301
Principal Investigator: Dina Randazzo, MD

Cleveland Clinic
Cleveland, Ohio,
United States, 44195

Contact: Cathy Brewer,RN, brewerc1@ccf.org
Phone: 216-444-0437
Principal Investigator: Michael Vogelbaum, MD, PhD

Oregon Health and Science University
Portland, Oregon,
United States, 97239

Contact: Michael McGehee, nsgclinicalresearch@ohsu.edu
Phone: 503-494-4988
Principal Investigator: Seunggu Han, MD

Hospital of the University of Pennsylvania Health System
Philadelphia, Pennsylvania,
United States, 19104

Contact: Timothy Prior, NCRD-BTC@uphs.upenn.edu
Phone: 215-662-6832
Principal Investigator: Steven Brem, MD

Cancer Therapy and Research Center At The University of Texas Health Science Center At San Antonio
San Antonio, Texas,
United States, 78229

Contact: Epp Goodwin, CTRC-ReferralCenter@uthscsa.edu
Phone: 210-450-5789
Principal Investigator: Andrew Brenner, MD